Form D · Pharmaceuticals
PROVECTUS BIOPHARMACEUTICALS, INC.
Knoxville, TN · CIK 0000315545
Offering snapshot reported Jul 17, 2024 · SEC filing
- Reported sold
- Yet to sell Offering amount: $10M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 17, 2024 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Oct 28, 2022 | Initial | $317,500 | No comparison | 2 | SEC filing |
| Aug 30, 2021 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Oct 15, 2014 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Apr 17, 2014 | Initial | $3,373,250 | No comparison | 17 | SEC filing |
| Sep 26, 2013 | Initial | $7,798,037 | No comparison | 67 | SEC filing |
| Mar 8, 2013 | Initial | $2,550,000 | No comparison | 3 | SEC filing |
| Nov 19, 2012 | Initial | $2,034,675 | No comparison | 5 | SEC filing |
| Aug 3, 2012 | Initial | $2,077,796 | No comparison | 16 | SEC filing |
| Mar 22, 2012 | Initial | $499,999 | No comparison | 6 | SEC filing |
| May 5, 2011 | Initial | $4,615,300 | No comparison | 26 | SEC filing |
| May 13, 2010 | Initial | $200,000 | No comparison | 0 | SEC filing |
| Apr 6, 2010 | Initial | $1,271,900 | No comparison | 14 | SEC filing |
| Mar 26, 2010 | Amendment | $7,613,327 | $4,901,327vs Jun 30, 2009 | 90 | SEC filing |
| Mar 24, 2010 | Initial | $7,937,499 | No comparison | 36 | SEC filing |
| Aug 7, 2009 | Amendment | $4,507,176 | $1,795,176vs Jun 30, 2009 | 90 | SEC filing |
| Jun 30, 2009 | Initial | $2,712,000 | No comparison | 47 | SEC filing |
| Jun 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 30, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 4, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-519084
Source: Form D, filed Jul 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Webster Bailey | Director |
| Peter R. Culpepper | Executive |
| Craig Dees | Director, Executive |
| H. Craig Dees | Director, Executive |
| Stuart Fuchs | Director |
| Bruce Horowitz | Director, Executive |
| Jan Koe | Director |
| John Lacey, Iii | Director |
| Kelly M. Mc Masters | Director |
| Edward Pershing | Director |
| Ed Pershing | Director |
| Heather Raines | Executive |
| Dominic Rodrigues | Director |
| Tim Scott | Executive |
| Timothy C. Scott | Director, Executive |
| Alfred E. Smith Iv | Director |
| Eric Wachter | Executive |
| Eris A. Wachter | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
800 S. Gay Street Suite 1610
Knoxville, TN, 37929
Knoxville, TN, 37929